Distinct Escherichia coli transcriptional profiles in the guts of recurrent UTI sufferers revealed by pangenome hybrid selection
- PMID: 39487120
- PMCID: PMC11530686
- DOI: 10.1038/s41467-024-53829-7
Distinct Escherichia coli transcriptional profiles in the guts of recurrent UTI sufferers revealed by pangenome hybrid selection
Abstract
Low-abundance members of microbial communities are difficult to study in their native habitats, including Escherichia coli, a minor but common inhabitant of the gastrointestinal tract, and key opportunistic pathogen of the urinary tract. While multi-omic analyses have detailed interactions between uropathogenic Escherichia coli (UPEC) and the bladder mediating urinary tract infection (UTI), little is known about UPEC in its pre-infection reservoir, the gastrointestinal tract, partly due to its low relative abundance (<1%). To sensitively explore the genomes and transcriptomes of diverse gut E. coli, we develop E. coli PanSelect, which uses probes designed to specifically capture E. coli's broad pangenome. We demonstrate its ability to enrich diverse E. coli by orders of magnitude, in a mock community and in human stool from a study investigating recurrent UTI (rUTI). Comparisons of transcriptomes between gut E. coli of women with and without history of rUTI suggest rUTI gut E. coli are responding to increased oxygen and nitrate, suggestive of mucosal inflammation, which may have implications for recurrent disease. E. coli PanSelect is well suited for investigations of in vivo E. coli biology in other low-abundance environments, and the framework described here has broad applicability to other diverse, low-abundance organisms.
© 2024. The Author(s).
Conflict of interest statement
T.S.J., H.C.M., and A.M.E. are co-inventors on a patent application related to this study. H.C.M. is an employee of and holds equity in Inceptive Nucleics, Inc., and is a co-inventor of a patent related to work in this study (US11332783B2). T.S.J. is an employee and holds equity in Seres Therapeutics, Inc. The remaining authors declare no competing interests.
Figures





Update of
-
Distinct Escherichia coli transcriptional profiles in the guts of recurrent UTI sufferers revealed by pangenome hybrid selection.bioRxiv [Preprint]. 2024 Jun 1:2024.02.29.582780. doi: 10.1101/2024.02.29.582780. bioRxiv. 2024. Update in: Nat Commun. 2024 Nov 2;15(1):9466. doi: 10.1038/s41467-024-53829-7. PMID: 38463963 Free PMC article. Updated. Preprint.
References
-
- Foxman, B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med.113, 5S–13S (2002). - PubMed
-
- The Lancet. Balancing treatment with resistance in UTIs. Lancet391, 1966 (2018). - PubMed
-
- Ajiboye, R. M. et al. Global spread of mobile antimicrobial drug resistance determinants in human and animal Escherichia coli and Salmonella strains causing community-acquired infections. Clin. Infect. Dis.49, 365–371 (2009). - PubMed
-
- Karlowsky, J. A., Hoban, D. J., Decorby, M. R., Laing, N. M. & Zhanel, G. G. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob. Agents Chemother.50, 2251–2254 (2006). - PMC - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
- R01DK121822/U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- R01 AI165915/AI/NIAID NIH HHS/United States
- U19AI110818/U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- R01AI165915/U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- R01 DK121822/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical